SCHEMBL1921441

SCHEMBL1921441

COC(=O)N(Cc1ccc(-c2cccc(CC(=O)O)c2)cc1)C1c2ccccc2-c2ccccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SELL P14151 2/20 0.43
▸ SELP P16109 2/20 0.43
▸ ENPP2 Q13822 2/20 0.42
▸ ABCC4 O15439 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ PTGS1 P23219 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ NR1H4 Q96RI1 3/20 0.41
▸ TBXA2R P21731 1/20 0.40
▸ PTGDR Q13258 1/20 0.40
▸ PTGDR2 Q9Y5Y4 1/20 0.40
▸ PTGES O14684 1/20 0.40
▸ RORC P51449 1/20 0.39
▸ GRIN2D O15399 1/20 0.39
▸ GRIN3B O60391 1/20 0.39
▸ GRIN1 Q05586 1/20 0.39
▸ GRIN2A Q12879 1/20 0.39
▸ GRIN2B Q13224 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3064761 0.76 LOXL2 (0.49) —
SCHEMBL7269532 0.76 OPRM1 (0.42) SELLSELPENPP2GAATSHR
SCHEMBL2651976 0.74 GCGR (0.49) —
SCHEMBL4600049 0.73 GPR3 (0.41) GAATSHR
SCHEMBL31355068 0.73 GPR3 (0.41) GAATSHR
SCHEMBL28330790 0.72 SLC6A2 (0.50) LMNAGAANR1H4
SCHEMBL9171866 0.72 PTGDR2 (0.39) SELLSELPGAATSHRPTGS1
SCHEMBL31355071 0.72 KMT2A (0.40) LMNAGAATSHR
SCHEMBL3202976 0.72 KMT2A (0.40) LMNAGAATSHR
SCHEMBL7432374 0.72 ENPP2 (0.43) ENPP2ABCC4LMNAGAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299023-B2 Neuropeptide-2 receptor (Y-2R) agonists HOFFMANN-LA ROCHE INC. (US) 2012-10-30 — — US disclosed
EP-2326666-A1 NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS AND USES THEREOF F. Hoffmann-La Roche AG (CH) 2011-06-01 — — EP disclosed
WO-2010031707-A1 NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2010-03-25 — — WO disclosed
US-20100069307-A1 NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS DANHO WALEED 2010-03-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069307-A1 NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS NPY2R, NPY1R, NPY4R SELL 1913/4885SELP 2483/4885ENPP2 382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback